Insuman Basal (Insulin Human)

Insulin human mimics the natural hormone produced by the pancreas. It binds to insulin receptors on muscle, fat and liver cells, activating signaling pathways that increase glucose uptake, inhibit hepatic glucose production, and promote storage of glucose as glycogen, thereby lowering blood‑sugar concentrations.

The dose of Insuman Basal is individualized. A qualified prescriber determines the starting amount, titration schedule and total daily dose based on the patient’s age, weight, renal function, current glucose control and concurrent therapies. Patients should follow the prescriber’s written instructions precisely.

Insulin is generally considered the preferred glucose‑lowering therapy during pregnancy because it does not cross the placenta in harmful amounts. However, the decision to use Insuman Basal should be made by a healthcare professional who weighs maternal benefits against any potential fetal risk. Breast‑feeding mothers should also consult their clinician.

To request Insuman Basal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and the necessary import documentation.

Insuman Basal contains human insulin, whereas many newer basal analogues (e.g., insulin glargine or detemir) are modified molecules with altered pharmacokinetics. Human insulin typically has a shorter duration of action and may require twice‑daily dosing, while analogues often provide a flatter, once‑daily profile. Choice depends on clinical goals, patient preference and cost considerations.

Insuman Basal must be stored in a refrigerator at 2–8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, but any cloudiness or discoloration warrants disposal.

Insuman Basal is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to reduce lipodystrophy. Dosing time is usually once or twice daily, as directed by the prescriber, and the injection should be given at the same time(s) each day for consistency.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognise early signs of low blood glucose, carry rapid‑acting carbohydrate, and seek immediate medical help if a severe reaction occurs.

Insuman Basal is contraindicated in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It should also be avoided in patients experiencing hypoglycaemia unresponsive to treatment, or in those with severe renal or hepatic failure where insulin clearance is markedly reduced, unless closely supervised by a clinician.